

Disclosures

Personal Commercial (9)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
89bio	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Amarin	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Amgen Inc.	Speaker's Bureau	Modest (< \$5,000)	Prevention
Amryt	Speaker's Bureau	Modest (< \$5,000)	Prevention
Dalcor	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Esperion	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Esperion	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Immunovant	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Kowa	Research/Research Grants ‡ PROMINENT	Modest (< \$5,000)	Prevention

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Atherometabolism Institute † Pfizer Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Atherometabolism Institute † Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Atherometabolism Institute † Immunovant	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Utah Lipid Center † Regeneron	Research/Research Grants ‡ Pediatric trial of evinacumab	Significant (>= \$5,000)	Prevention

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
Self				
2022	Icosapent ethyl in CVD risk reduction	Plaintiff	Patent issues over use of icosapent ethyl to prevent CV death in mixed dyslipidemia	Significant (>= \$5,000)
2020	New onset diabetes with atorvastatin use	Plaintiff † Heard, Robins, Cloud and Black, LLP	class-action lawsuit against Pfizer regarding failure to disclose risk of new-onset diabetes with atorvastatin use	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 3/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 3/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 3/19/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.